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Adenosine 5=-monophosphate-activated protein kinase (AMPK) is a key metabolic sensor that responds to cellular energy deprivation and/or chemical and physical stresses. AMPK is ubiquitously expressed and responds to increases in the AMP-to-ATP ratio via AMP binding and catalytic activation by upstream kinases including the tumor suppressor protein LKB1 and transforming growth factor-␤-activated kinase 1 (19, 37, 47, 48) . AMPK can also be activated in an AMP-independent manner via neurohormonal signals controlling appetite as well as by direct phosphorylation by Ca 2ϩ -dependent CamKK-␤ (19, 37, 47, 48) . In a traditional sense AMPK responds to stimuli by inhibiting ATP-depleting processes such as cholesterol and protein synthesis while promoting carbohydrate and lipid metabolism, thus increasing ATP synthesis and restoring energy homeostasis within the cell (47, 48) . However, more recently it has been suggested that AMPK plays a significant role in cellular growth arrest (12, 18, 32, 35, 53) , making it an ideal candidate for studies targeted at reducing VSM growth. It has been reported that AMPK has the ability to enhance vascular relaxation (12, 46) and to inhibit vessel growth (38) , and it has been implicated in G 0 /G 1 cell cycle arrest of commercial VSMCs (22) . Notably, we recently reported that AMPK has capacity to communicate with protein kinase A in growth inhibition of primary VSMCs (53) . This demonstration of the functionality of AMPK within the vasculature, particularly its growth-reducing capacities, justifies further investigation into AMPK as a potential therapeutic target for use in reducing VSM growth disorders.
In intact blood vessels the progression of growth disorders culminates from the activation of VSMCs within the medial wall, thus promoting their luminal migration, proliferation, and matrix deposition and ensuing neointimal development. The physical migration of cells along a substrate is dependent on highly dynamic actin cytoskeletal and focal adhesion turnover (2, 49) . It has been reported that AMPK has the capacity to phosphorylate and deactivate actin-associated vasodilator-activated serum phosphoprotein (VASP) (5) and to increase focal adhesion integrity and actin bundling (36) . Therefore, given the antigrowth and potential antimigratory capacities of AMPK, it makes sense that AMPK may play a major role in the reduction of VSM growth. This warrants further investigation to gain insights into the mechanisms employed by AMPK to reduce VSM proliferation and migration.
The purpose of this study was to examine our hypothesis that AMPK inhibits VSM growth by inhibiting cellular migration and cell-cycle progression and actin cytoskeletal and focal adhesion dynamics. We propose that these mechanisms are employed by AMPK in an effort to reduce VSM growth and that induction of these signaling events will effectively reduce neointima formation of rat carotid arteries following balloon injury. In summary, findings show that AMPK significantly reduces neointimal development through cytostatic inhibition of VSMC proliferation and reduction in migration. Mechanistic data support roles for AMPK in the stabilization of the actin cytoskeleton and in the enhancement of focal adhesion and ECM stability. These findings provide strong evidence for AMPK as a physiological regulator of VSM growth and offer support for its continued study.
MATERIALS AND METHODS
This investigation was approved by the East Carolina University Animal Care and Use Committee and conformed to the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Publication No. 85-23, Revised 1996).
Materials
5-Aminoimidazole-4-carboxamide-1-␤-D-ribofuranoside (AICAR) was purchased from Toronto Research Company (North York, Ontario, Canada) and Invitrogen (Carlsbad, CA), compound C (CC) was purchased from Invitrogen, and A-769662 was purchased from Tocris (Minneapolis, MN). All primary antibodies were purchased from Abcam (Cambridge, MA) or Cell Signaling (Danvers, MA) and were targeted against the following: total AMPK (1:1,000), phospho (p)AMPK Thr172 (1:1,000), total VASP (1:1,000), or pVASPThr278 (1:1,000), and ␤-actin (1:1,000). Antibodies were diluted in IRDye blocking buffer (Rockland; Gilbertsville, PA) or 1% BSA in PBS (Gemini; Stoneham, MA). IRDye secondary antibodies (1:1,000; Rockland) and FITC-or Texas Red-conjugated secondary antibodies (1:10,000; Rockland) were used for protein detection, whereas 1,5-bis{[2-(methylamino)ethyl]amino}-4,8-dihydroxy anthracene-9, 10-dione (Draq-5; 1:10,000; Cell Signaling) and Sapphire 700 (1: 1,000; Li-Cor; Lincoln, NE) were used for DNA staining and protein normalization. Propidium iodide and RNAse for cell cycle analysis were purchased from Invitrogen. Alexa Fluor-conjugated deoxyribonuclease I or phalloidin stains for G-and F-actin were purchased from Invitrogen.
Methods
Rat carotid artery balloon injury. Experimental balloon injury was performed on the left carotid artery of male Sprague-Dawley rats (500 g) as we have previously described (56, 57) . Briefly, animals were anesthetized with ketamine (90 mg/ml)-xylazine (10 mg/ml) (1.0 ml/kg body wt ip), and a Fogarty 2-Fr embolectomy catheter was introduced through an arteriotomy site and advanced through the left carotid artery, inflated, and withdrawn three times to achieve arterial injury. The exposed portion of the left carotid artery was treated accordingly, the tissues were closed, and the animals were given meloxicam (1 ml/kg) for pain.
Tissue processing and staining. Two weeks following surgery, animals were anesthetized and euthanized by pneumothorax and exsanguination, respectively. Tissues were perfusion fixed and paraffin embedded, and standard staining techniques were used to analyze vessel growth as we have previously described (56) . Briefly, neointimal and medial wall areas were measured and their ratio was calculated (as neointimal area/medial wall area) as a standard measure of remodeling. Also, perimeters of the internal and external elastic laminae were measured to obtain vessel circumferences (56) . Additionally, a small cohort of animals were euthanized at varying times, and carotids were excised and homogenized for protein analysis as described (58) .
Cell culture. Primary VSMCs were isolated from male SpragueDawley rat thoracic aorta (100 -125 g; Charles River) by collagenase and elastase digestion and characterized morphologically as previously described (11) . VSMCs were cultured in Dulbecco's modified Eagle's medium, supplemented with fetal bovine serum (FBS, 0.5-10%), 2 mM L-glutamine, and 1:500 dilution of 50 g/ml Primocin at 37°C in 95% air-5% CO 2. Cells were serially split and used through passage 6 (7, 53) .
Protein detection. VSMCs were seeded in 96-well plates and, once confluent, were treated with specified agents. After treatment, cells were formalin fixed, and protein phosphorylation was determined by In-Cell Western blot analysis as recently described (1, 26, 53) . Briefly, fixed cells were permeabilized with 0.1% Triton-X, blocked with A B Fig. 3 . AICAR increases AMPK signaling in rat primary VSMCs. Cells were treated with AICAR (1 mM, 60 min) and/or compound C (CC; 10 M, 60 min) and AMPK Thr172 phosphorylation (A) and AMPK activity (B) were measured respectively by In-Cell Western blot analysis and enzyme-specific activity assay. AICAR significantly increased phosphorylation of both AMPK Thr172 and AMPK activity after 1 and 24 h, both which were reversed by CC. CC alone exerted no effect on basal Thr172 phosphorylation or AMPK activity. Data are presented at pAMPK Thr 172/total AMPK and normalized to DNA content (1,5-bis{[2-(methylamino)ethyl]amino}-4,8-dihydroxy anthracene-9,10-dione (Draq-5)/Sapphire 7) or absorbance at 540 nm for activity, and within each study (n ϭ 5-7). P values Ͻ 0.05 were considered statistically significant. **P Ͻ 0.005 compared with control; ***P Ͻ 0.001 compared with control; #P Ͻ 0.05 compared with respective activator treatment.
IRDye blocking buffer, and treated with rabbit anti-rat primary antibodies (1 h; room temperature). Target proteins were infrared labeled, and DNA was stained for protein normalization. Fluorescence was detected and analyzed using Li-Cor Odyssey Infrared Imaging System and software. Traditional Western blot analyses were performed on primary cell lysates as previously described (28, 34, 59) to confirm AMPK activation and to complement In-Cell Western blot analysis data.
Assessment of AMPK and Ser/Thr phosphatase activities. Specific activities for AMPK and Ser/Thr phosphatases were detected in treated cells lysed in buffer consisting of 50 mM Tris (pH 6.8), 1% SDS, 0.1% Triton, protease inhibitor cocktail (Thermo), and phosphate inhibitor cocktail (except for phosphatase activity; Thermo) and added to wells of a 96-well microtiter plate. ELISA-based activity assays were performed per manufacturer's instructions (29, 41, 53) . Briefly, AMPK (MBL International, Woburn, MA) activity was assessed using a mouse insulin receptor substrate phosphoserine-789 reporter with horseradish perioxidase chemiluminescence at 450 nm. Ser/Thr phosphatase (Invitrogen) activity was measured via 6,8-difluoro-4-methyl-umbelliferyl phosphate substrate that generates DiFMU at 450 nm in proportion to phosphatase activity. For specific protein phosphatase-2A (PP-2A) activity, NiCl 2 (1 mM) was added to the reaction buffer according to the manufacturer's instructions and DiFMU generation was measured.
Immunocytochemistry. VSMCs were seeded on glass coverslips and allowed to adhere. Cells were treated for 1-48 h with select pharmacological agents, formalin fixed, permeabilized (0.1% Triton-X), and blocked with 3% BSA in PBS plus 1% Tween-20. Protein IgG reactions were carried out using selective primary antibodies followed by counterstaining with fluorescently tagged secondary antibodies (FITC and Texas Red). Fluorescently tagged phalloidin and deoxyribonuclease I were used to detect F-and G-actin, respectively.
Immunofluorescence. Confluent VSMCs were treated with select pharmacological agents for 1-24 h and then trypsinized, formalin fixed, permeabilized, and blocked in suspension as described above. Select cellular proteins were detected in suspension as described, and cells were analyzed by flow cytometry (Accuri C6 Flow Cytometer) using CFlow Plus software (Accuri) (24) .
Cell cycle analysis. Cells were plated in 12-well plates at 80,000 cells/well in complete media until ϳ50% confluent. Cells were quiesced in 0.5% FBS for 24 h, followed by treatment in complete growth media (Dulbecco's modified Eagle's medium, 10% FBS, Primocin), containing select pharmacological agents for 24 h. Cells were trypsinized and stained with propidium iodide (Invitrogen) per manufacturer's recommendations (26, 53) . The fraction of cells present in each phase of the cell cycle was assessed by flow cytometry (Accuri).
Cell proliferation and viability analyses. VSMCs were plated in six-well plates at 180,000 cells/well in complete media until ϳ50% confluent. Cells were quiesced in 0.5% FBS for 24 h, followed by treatment in complete growth media for 48 h as described. Cells were trypsinized, and proliferation and viability were assessed through automated cell counting with trypan blue exclusion staining (ViCell, Beckman Coulter).
Cell migration analyses. VSMCs were seeded at 180,000 cells/ml in the upper chamber of a Fluorblok transwell system (BD) in complete media and allowed to adhere. Cells were treated for 1 h following staining with CellTracker Green (10 M; Invitrogen). Serum-free media was applied to the upper chamber containing the same original treatment, and 10 ng PDGF-␤ were applied to the bottom chamber as a chemoattractant (53, 65) . Cell migration was assessed from time 0 through 18 h by bottom-read fluorescence at 525 nm (Tecan Infinite M200). Additionally, with the use of a wounding assay, cells were grown to confluence in six-well plates and select pharmacological agents were added to the growth media for 1 h. Following treatment, cells were wounded with a 2-mm blade, and the rate of wound healing was assessed by photomicrography through 24 h.
Matrix metalloproteinase activity analysis. Matrix metalloproteinase (MMP) activity was assessed by matrix gel zymography (31) . Briefly, conditioned media was electrophoresed in a 10% zymogram gel containing 1 mg/ml gelatin. The gel then underwent a series of washings at room temperature for 2 h, followed by an overnight A B µ µ Fig. 4 . AMPK induces cell-cycle arrest and inhibits vascular smooth muscle cell (VSMC) proliferation. Cells were treated with AICAR (1 mM) and/or CC (10 M) following overnight quiescence. A: cell numbers were quantified after 48 h by automated cell counting and trypan blue exclusion. B: cell-cycle progression after 24 h was analyzed by flow cytometry using propidium iodide. AICAR significantly reduced cell numbers and inhibited cell cycle progression revealed by increased G0/G1 and S and reduced G2/M cell numbers. Of note, CC alone significantly reduced cell numbers compared with vehicle controls (A) and significantly reduced cell numbers in G2/M. Trypan blue exclusion failed to detect any differences in cell viability in any treatment group (data not shown). P values Ͻ 0.05 were considered statistically significant after multiple comparisons and 2-way ANOVA. **P Ͻ 0.005 compared with control; ***P Ͻ 0.001 compared with control; #P Ͻ 0.05 compared with respective activator treatment.
incubation at 37°C in renaturing buffer. The gel was then stained with Coomassie blue and visualized using an Epson Perfection V750 Pro scanner. Proteolytic activity was assessed as the density of a white band (indicative of enzymatic digestion) on a dark blue field. Additionally, expression of the tissue inhibitor of metalloproteinase (TIMP) was analyzed from the conditioned media of treated cells by traditional Western blot analysis as we have previously described (34, 59) . Statistical analyses. Data were analyzed using Excel 2011 (Microsoft) and Sigma Plot 11.2 (SPSS). All data sets were tested for normal distribution and met the homogeneity prerequisites for analysis of variance (ANOVA). One-way ANOVA and Tukey's post hoc multiple comparison tests were used to detect changes between individual groups. Two-way ANOVA with multiple comparisons, and Tukey's post hoc tests were used for protein phosphatase analysis, migration, and cell cycle analysis to detect significance among groups. Data are expressed as means Ϯ SE, with P Ͻ 0.05 considered as statistically significant.
RESULTS

Systemic and Local AICAR Inhibit Vascular Remodeling
Previous work by our laboratory established both systemic pretreatment (60) and localized dosing (61, 62) of pharmacological agents concomitant with the rat carotid artery model of vascular injury (56, 59 -61) . In similar fashion, in the current study we assessed the effects of systemic pretreatment as well as localized delivery of the well-characterized AMP-mimetic AICAR (8, 38, 53, 54, 63) (0.5 g/kg body wt systemic; 1 mg local) on vascular remodeling in rat balloon-injured carotid arteries. Additionally, we used the direct, nonmetabolic AMPK-activating small molecule A-769662 (15, 20, 42, 51) (1 mg) with localized delivery to verify specificity of AICARmediated AMPK effects. First, to verify these treatment regimens on uninjured vessels, daily intraperitoneal dosing with AICAR for 2 days or localized perivascular delivery of AICAR or A-769662 each significantly induced AMPK activity assessed by Thr172 phosphorylation (10) in carotid artery lysates compared with vehicle (NaCl or DMSO)-treated control vessels (Fig. 1) . Two weeks after balloon injury, both AICAR and A-769662 significantly reduced neointima formation compared with vehicle-treated controls using both systemic (Fig. 2 , A and D) and localized (Fig. 2, B , C, E, and F) dosing regimens. Notably, comparable levels of growth inhibition were observed between localized AICAR and A-769662. Vessel circumferences, measured as internal and external elastic lamina lengths, were obtained to rule out anatomical vessel distension as a contributor of the observed remodeling but were found not to be significantly different in any treatment group compared with vehicle controls (data not shown).
AICAR Increases AMPK Activity in Primary VSMCs
In rat primary VSMCs, AICAR (1 mM) significantly enhanced Thr172 phosphorylation of AMPK at 1 h (8, 14, 53, 63) , which continued through 24 h (Fig. 3A) . This activating phosphorylation was completely reversed by the AMPK inhibitor CC (10 M) at both time points (8, (52) (53) (54) , yet CC alone did not alter basal (untreated) Thr172 phosphorylation levels. In addition, an AMPK-specific activity assay verified that the observed increases in Thr172 phosphorylation correlate with increased activity at both 1 and 24 h (Fig. 3B) . Again, CC alone had no impact on basal AMPK activity.
AMPK Inhibits VSMC Proliferation
In rat primary VSMCs, AICAR (1 mM) significantly inhibited viable cell numbers after 48 h, and CC largely reversed this antiproliferative effect (Fig. 4A) A: with addition of NiCl2 (1 mM) to the reaction buffer, PP-2A-specific activity was tested and revealed that AICAR significantly elevated PP-2A activity and was reversed by CC. Treated cells underwent fractionation so that nuclear lysates could be electrophoresed and probed for cdc2/cyclin B expression. B: cyclin B expression was significantly decreased in AICARtreated cells in a CC-reversible fashion compared with controls. Two-way ANOVA with Tukey's post hoc testing was used for multiple comparisons across time points as well as within each treatment group for phosphatase activity, and 1-way ANOVA detected differences among groups for protein analysis. P values Ͻ 0.05 across time within each group were considered statistically significant. **P Ͻ 0.005 compared with control; #P Ͻ 0.05 compared with respective activator treatment.
cell viability were not observed in any treatment group, and overall viability ranged between 85 and 90% after 24 h (data not shown). With the use of flow cytometry, AICAR significantly reduced G 2 /M cell populations and significantly increased S-phase cell populations after 24 h compared with vehicle-treated cells, and the changes in the S and G 2 /M phases were fully reversed with concomitant CC (Fig. 4B) . AICAR also induced a nonsignificant increase in the G 0 /G 1 cell populations, which corresponds well with the decrease in G 2 /M cell populations. Interestingly, CC alone significantly reduced cell numbers after 48 h and nonsignificantly reduced cells in G 2 /M after 24 h.
It has been suggested that PP-2A has the ability to inhibit G 2 /M cell-cycle progression by inhibiting the cdc/cyclin B complex (24) . In our study, with the use of a PP-2A-specific activity assay in primary VSMCs, data show that AMPK promotes PP-2A activity (1 mM AICAR; 24 h) in a CCreversible fashion (Fig. 5A) . Concomitantly, cells treated with AICAR over 24 h showed significant reductions of cyclin B in nuclear fractions compared with controls, which was fully reversed by CC (Fig. 5B) .
AMPK inhibits VSMC migration. With the use of a transwell chemotaxis assay, AICAR (1 mM) significantly inhibited PDGF-␤ (20 ng/ml)-induced VSMC migration over 18 h (Fig. 6A) . Whereas CC alone exerted no effect on basal levels of migration, AICARmediated inhibition of migration was partially reversed in the presence of CC and, per a two-way ANOVA, was not statistically different from vehicle controls (P ϭ 0.412). In complement, a wound-healing assay on serum-stimulated confluent VSMCs showed that AICAR (1 mM) significantly reduced migration over a 24-h period (Fig. 6, B and C) .
AMPK Promotes Actin Cytoskeleton Stability
Actin-associated VASP acts as an anticapping protein that promotes actin nucleation and filament elongation required for , and PDGF-stimulated (10 ng/ml) chemotaxis was determined using a modified Boyden chamber apparatus and bottom-read fluorescence at 525 nm between 0 and 18 h. AICAR significantly reduced cell migration, which showed a nonsignificant reversal with simultaneous CC (A). CC alone failed to alter basal migration compared with controls. B: cells were grown to confluence in 6-well plates and treated the same as in A. A 2-mm blade was used to injure the cell monolayer, and photomicrographs were taken through 24 h. Photomicrographs show vehicle-and AICAR-treated cells immediately after scrape injury (time ϭ 0) and after 24 h. C: measurement of the wound area reveals that AMPK significantly inhibits VSMC wound healing after 24 h. Two-way ANOVA with Tukey's post hoc testing was used for multiple comparisons across time points as well as within each treatment group. P values Ͻ 0.05 across time within each group were considered statistically significant. *P Ͻ 0.05 compared with control; **P Ͻ 0.005 compared with control.
cell migration (3, 4, 9, 50) . Upon site-specific phosphorylation, VASP is rendered inactive and actin filaments are capped and polymerization stops; hence, phosphorylated VASP can serve as an antimigratory factor. It has been shown that VASP possesses an AMPK-specific phosphorylation site Thr278 (5) . In this study we verify that AICAR (1 mM) significantly increases pVASP Thr278 compared with vehicle controls after 1 h, and this was completely reversed with CC (10 M) (Fig. 7) . Of note, CC alone had no effect on Thr278 phosphorylation. Immunofluorescent flow cytometry for G-and F-actin shows that AICAR significantly increases the ratio of G-to F-actin after 1 h (Fig. 8A) , which continues through 24 h (Fig. 8B) . At both times, CC fully reversed basal and AICAR-induced ratios of G-to F-actin. In support, phalloidin staining for F-actin suggests that AICAR significantly increases (ϳ55%; 9 Ϯ 2 control vs. 20 Ϯ 3 AICAR/field of view) actin bundling and stress fiber formation in primary VSMCs compared with vehicle-treated cells, which exhibited an organized parallel arrangement of actin fibers (Fig. 8C) .
AMPK Promotes Focal Adhesion Stability
Focal adhesion (FA) kinase (FAK) is largely responsible for focal adhesion turnover and the promotion of cell detachment and migration along a substratum (30, 49, 55) . In rat primary VSMCs, pFAK Tyr397, a necessary event for kinase activity (55) , was significantly elevated with addition of PDGF-␤ (10 ng/ml) after 1 h, yet AICAR significantly reduced this activated phosphorylation state of FAK in the presence of PDGF-␤ down to control levels (Fig. 9) .
Another essential component of a functional focal adhesion is paxillin (36, 55) . Immunostaining for paxillin on adherent VSMCs shows marked cytoplasmic staining in vehicle-treated cells yet significant nuclear staining in AICAR-treated cells after 24 h (Fig. 10A) . Immunofluorescence detected by flow cytometry revealed that the total paxillin content was increased after 24 h compared with controls (Fig. 10B) . It is suggested that paxillin is differentially expressed in each cellular compartment, which confers a pro-or antimigratory signal within the cell (21, 64) . In this manner, quantitative data from immunostaining suggest that AICAR promotes nuclear and membranous accumulation of paxillin while preventing cytosolic accumulation after 24 h compared with vehicle-treated cells (Fig. 10C) .
AMPK Promotes Cell/ECM Stability
The ECM provides a substrate for cellular binding as well as a material on which to exert forces necessary for movement. Growth factors and prosynthetic cytokines promote the production and secretion of MMPs that degrade the ECM and thus regulate cell motility (39) . The gelatinases MMP-2 and MMP-9 are integral to VSMC migration (6, 25, 39) . MMPspecific column zymography on conditioned media from vehicle-or AICAR-treated VSMCs after 24 h revealed that whereas no differences were observed in MMP-2 activity between these cohorts (Fig. 11A) , AICAR significantly reduced MMP-9 activity compared with vehicle controls (Fig. 11B) . Regarding MMPs, TIMP-1 acts as an extracellular regulator capable of tightly controlling MMP-9 activity. In our study TIMP-1 expression approximately doubled (P Ͻ 0.01) in conditioned media from AICAR-treated VSMCs compared with vehicle controls after 24 h (Fig. 11C) .
DISCUSSION
Findings in this study support our hypothesis that AMPK has capacity to reduce arterial remodeling via inhibition of VSMC proliferation and migration. Data suggest that AMPK, stimulated via two distinct pharmacological approaches, operates by provoking cell-cycle arrest through a PP-2A/cyclin B mechanism and by preventing cytoskeletal/focal adhesion restructuring necessary for VSMC migration. These findings offer unique insight into AMPK signaling as a novel system with significant therapeutic potential in the remediation of vascular growth disorders. Smooth muscle-mediated vascular remodeling plays a pivotal role in the onset and complication of vasculoproliferative diseases (23, 33, 44) ; therefore, targeted therapies are of great clinical importance. Data presented here lend strong support for AMPK as a biologically active signaling molecule within VSM capable of curbing cell migration and proliferation and ECM turnover, all major players in pathological vascular remodeling.
Using the well-established balloon injury model to induce VSMC-mediated vessel remodeling (56, 60, 62) , we illustrate here that both systemic dosing and local application of the AMPK agonist AICAR is sufficient at inducing AMPK activity and at markedly reducing neointimal formation (Figs. 1 and 2 ). The use of AICAR and CC has been established in our laboratory (53) and by others to respectively promote or inhibit AMPK activity, and both agents have been used in vivo (13, 38) and in vitro (8, 14, 53, 63) in VSM. In an effort to confirm the results observed by treatment with AICAR, we also used a specific and nonmetabolic agonist of AMPK, the small molecule A-769662. This agent has been documented to directly activate AMPK in cell-free systems, in intact cells, and in vivo without the side effects associated with the more traditional Fig. 7 . AMPK inhibits vasodilator-activated serum phosphoprotein (VASP)-mediated actin anticapping. Cells were treated with AICAR (1 mM, 60 min) and/or CC (10 M, 60 min), and VASP Thr278 phosphorylation was measured by In-Cell Western blot analysis. AICAR significantly induced pVASP Thr278, a proposed AMPK-specific site, which was fully reversed by CC. CC alone did not affect basal pVASP Thr278 status. Data are presented at pVASP Thr278/total VASP and normalized to DNA content (Draq 5/Sapphire 7) for 5-7 experiments. P values Ͻ 0.05 were considered statistically significant. ***P Ͻ 0.001 compared with control; #P Ͻ 0.05 compared with respective activator treatment.
AMPK-activating biguanides (15) . Importantly, A-769662 has been recently characterized for use in activating AMPK in vascular cells (42) . Specifically, in our current study, considering that the rat artery balloon injury model represents an in vivo proof of concept of our in vitro findings using isolated primary VSMCs, we used A-769662 in the in vivo model to further validate our findings with AICAR. The results obtained from localized treatment of injured vessels with A-769662 paralleled the results obtained with use of AICAR, thus confirming that the in vivo results as well as those obtained in vitro could be attributed to AMPK and not off-target drug-specific effects. Results using localized, perivascular delivery of AICAR or A-769662 are noteworthy and represent the first report demonstrating that local delivery of AMPK agonists immediately following intervention are biologically effective. Often, an a priori treatment to reduce vessel remodeling is not possible and systemic therapies can suffer from undesired side effects; however, localized delivery of an agent at the time of vascular intervention capable of reducing iatrogenic complications offers high clinical translation.
To examine the underlying mechanisms of growth suppression by AMPK, in rat primary VSMCs, following verification of the biological activity of AICAR (Fig. 3) , we show its ability to significantly reduce cell numbers through inhibition of cell-cycle progression (Fig. 4) . Flow cytometry revealed that AICAR exerts cytostasis in the G 0 /G 1 and S phases with concomitant reduction in progression through to the G 2 /M phase. Of note, no changes in cell viability were observed in any treatment group; therefore, the observed changes in cell number are likely due directly to alterations in cell-cycle progression and not from overt cytotoxicity. Additionally, a significant reduction in the cell numbers of CC-treated cells after 48 h was observed and is complemented by a nonsignificant reduction in G 2 /M cells after 24 h. It is possible to explain these phenomena by recent findings from collaborating investigators that revealed non-AMPK cytostatic effects of CC alone A B C Fig. 8 . AMPK promotes actin depolymerization and stress fiber formation. Cells were treated with AICAR (1 mM, 60 min) and/or CC (10 M, 60 min) and fixed and stained for F-actin (fluorescently-tagged phalloidin) or G-actin (fluorescently-tagged deoxyribonuclease I), and fluorescence was read by flow cytometry or visualized by fluorescence microscopy. Immunofluorescence reveals that AICAR promotes F-actin disassembly revealed by increased ratio of G-to F-actin in a CC-reversible fashion after (A) 1 h continuing through (B) 24 h. Notably, CC alone significantly reduced basal ratio of G-to F-actin compared with vehicle controls at both times. RFI, relative fluorescence intensity. C: cells were counterstained for F-actin and visualized using fluorescent microscopy. Representative photomicrographs reveal that AMPK promotes the disassembly of an organized F-actin array seen in vehicle-treated cells (arrowheads) and promotes actin bundling and stress fiber formation (stars). P values Ͻ 0.05 were considered statistically significant. **P Ͻ 0.005 compared with control; #P Ͻ 0.05 compared with respective activator treatment. (43) . Also, CC exhibits irreversible inhibitory actions on AMPK (16) , and without a functional AMPK system, it is plausible to speculate that the metabolic status of the cell could be compromised in such a way that after 48 h CC may induce cytotoxic effects. It was previously suggested that AMPK has the ability to promote cytostasis by cyclin-dependent kinase inhibition via a p53/p21 pathway in a commercialized human VSMC line (22) or through a Skp2/p27
Kip1 pathway in AMPK-deficient mouse VSMCs (52) . While intriguing and relevant to the current study, these previous reports seem somewhat contradictory; therefore, in addition to these findings, alternate mechanisms by which AMPK inhibits cell cycle progression are plausible. It has been reported that PP-2A has the ability to disrupt the cdc/cyclin B complex and inhibit G 2 /M progression. Since our cell cycle analysis reveals a large increase in S-phase cells, we investigated the hypothesis that PP-2A contributes to the mechanism for AMPK inhibition of VSMC proliferation. Data presented here suggest that AMPK induces PP-2A activity (Fig. 5A ) and concomitantly reduces cdc2/cyclin B expression after 24 h (Fig. 5B) , thus supporting the hypothesis that AMPK works, at least in part, through PP-2A to induce S-phase cytostasis.
In addition to proliferation, VSMC migration is pivotal in the pathophysiology of vessel remodeling. In this study we demonstrate that AMPK plays a key role in the inhibition of VSMC migration using two distinct experimental approaches. The physical movement of cells across a substrate is a complex process highly dependent on the actin cytoskeleton and its interface with focal contacts and the ECM. We present one of the first reports of how AMPK may act to inhibit VSMC migration, which could offer significant therapeutic insight for the curbing of disease processes that arise from an induction of cell migration. Novel data presented here reveal a possible mechanism by which AMPK inhibits VSMC migration. Actin polymerization and leading-edge formation are critical for directional cellular movement; however, AMPK impairs actin polymerization, presumably by inhibiting the anticapping potential of VASP through direct, site-specific phosphorylation (5). Here we observed significant enhancement of pVASP at the AMPK-sensitive T278 site by AICAR (Fig. 7) . The resulting impairment of actin polymerization is evidenced by concomitant accumulation of G-actin in the cytosol and increased stress fiber formation in cultured VSMCs (Fig. 8) . Thus these data convincingly argue that AMPK hinders cytoskeletal rearrangement necessary for VSMC migration as part of its mechanism of growth retardation.
Unique findings presented here also reveal that AMPK has the potential to inhibit focal adhesion turnover necessary for the movement of cells across or through substrata. We show that AICAR treatment impairs FAK activation by inhibiting Y397 phosphorylation (Fig. 9) , a necessary event for kinase activity (55) . Upon activation, FAK induces paxillin phosphorylation and targets GTPase activity at the focal adhesion, allowing for focal contact release (55) . Therefore, inhibition of FAK activity offers another possible mechanism by which AMPK mediates inhibition of migration. Additionally, it has been suggested that paxillin acts as a bidirectional membraneto-nucleus signaling molecule and that differential accumulation of paxillin in each cellular compartment is indicative of either a pro-or antisynthetic/migratory event (21, 64) . Our data reveal that AICAR prevents cytosolic accumulation of paxillin while promoting nuclear accumulation and membrane stability (Fig. 10) . Taken together, these data reveal a novel and intriguing antimigratory signaling network via AMPK-mediated inhibition of FAK and FA/paxillin dissociation, thereby reducing promigratory signals and promoting focal adhesion stability and growth suppression.
To more comprehensively address the biophysics of migrating and synthetic VSMCs, we assessed the activity of the ECM-degrading gelatinolytic MMPs. Upon activation, VSMCs produce and secrete MMP-2 and MMP-9 that act to degrade the ECM and that allow for VSMC expansion/migration and collagen deposition (6, 25, 39) . Here we show that AICAR selectively impairs MMP-9 activity (Fig. 11) , which we suggest promotes a more stable FA via reduced ECM degradation, thus increasing FA/substratum connectivity. Combined, these data suggest a novel role for AMPK in the reduction of MMP-9 activity that may play a key role in the inhibition of cellular migration via enhanced FA contacts, as well as matrix-based morphological changes in the vessel wall following injury. Based on our findings, a schematic is shown in Fig. 12 depicting cellular signaling actions of AMPK in VSM.
It is important to note that over the 2-wk time frame of our studies, there were no observable side effects of AICAR (following either local or systemic dosing) or local A-769662, particularly with body weight, fluid and food intake, or activity. We have previously shown that ϳ60% of the initial localized dose following injury is released over 24 h (58). This is a reasonable estimate for the duration of AICAR and Fig. 9 . AMPK inhibits focal adhesion kinase (FAK) activity. Cells were treated with PDGF-␤ (10 ng/ml, 60 min) with/without AICAR (1 mM, 60 min), and FAK Tyr397 phosphorylation was measured as an indication of kinase activity. PDGF-␤ induced significant pFAK Tyr397, which was fully reversed by AICAR. Data are presented at pFAK Tyr397/total FAK and normalized to DNA content (Draq 5/Sapphire 7) for 5ϩ separate experiments. P values Ͻ 0.05 were considered statistically significant. **P Ͻ 0.005 compared with control.
A-769662 bioactivity following localized dosing. Based on previous studies by our laboratory using localized dosing of agonists following balloon injury (26, 59, 60) , we used 1 mg AICAR and 1 mg A-769662 in this study. For systemic dosing of AICAR, previous reports (38) were used to determine an optimal dosing strategy that is devoid of potential side effects.
In conclusion, convincing data presented here provide strong evidence that AMPK is a desirable antigrowth target in VSM. Using the AMPK mimetic AICAR or the AMPK-activating small molecule A-769662, we present in vivo and in vitro data supporting our claims that AMPK abrogates neointimal formation and reduces VSMC proliferation and migration. Mechanistically, ample evidence suggests that AMPK acts to promote S-phase cytostasis and to inhibit cell migration via stabilizing FA contacts and reducing ECM turnover, thereby minimizing cytoskeleton reorganization necessary for migration and reducing promigratory signals between the membrane and the nucleus. These data paint a comprehensive picture of discrete AMPK-mediated cytostatic signaling networks that have significant clinical relevance in efforts to reduce vasculoproliferative pathologies.
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No conflicts of interest, financial or otherwise, are declared by the author(s). Fig. 10 . AMPK promotes antimigratory signaling through paxillin. Cells were treated with either AICAR (1 mM, 60 min), CC (10 M, 60 min), or a combination of both and then were either fixed and stained for paxillin or fractionated and probed for paxillin within each cell compartment. A: representative immunofluorescent images reveal a widely disperse paxillin staining in vehicle cells, whereas AICAR promotes paxillin accumulation within the nucleus and at focal contacts. B: protein analysis reveals that AMPK promotes paxillin expression after 24 h. C: paxillin expression is contained within the nuclear and membranous fractions, indicative of antimigratory signaling via paxillin. P values Ͻ 0.05 were considered statistically significant. *P Ͻ 0.05 compared with control; **P Ͻ 0.005 compared with control. Fig. 11 . AMPK inhibits matrix metalloproteinase (MMP)-9 proteolysis of VSMC extracellular matrix. Cells were treated with either AICAR (1 mM) or CC (10 M) for 24 h, and conditioned media and cell lysates were collected. A: a representative column gel zymogram for MMP activity reveals that whereas AMPK selectively inhibits MMP-9 activity in conditioned media of AICAR-treated cells compared with vehicle controls (Veh), no effects of AMPK were observed on MMP-9 activity in cell lysates or on MMP-2 activities in cell lysates or conditioned media. Positive controls (POS) are shown on the blot for both MMP-9 and MMP-2. A representative capture of a single zymogram gel is shown, yet the image was separated to exclude empty lanes (denoted as dashes for cell lysates). B and C: densitometry plots for MMP activity showing significant reduction in MMP-9 activity without noticeable changes in MMP-2 activity with AMPK stimulation. D: traditional Western blot analysis reveals that AMPK significantly increases expression of the tissue inhibitor of metalloproteinase (TIMP-1) in conditioned media of AICAR-treated cells compared with controls after 24 h. P values Ͻ 0.05 were considered statistically significant. **P Ͻ 0.005 compared with Cont. Fig. 12 . Schematic depicting the proposed role of AMPK in the control of vascular smooth muscle growth. In this diagram, blunt lines represent proposed inhibitory mechanisms, whereas arrows represent proposed stimulatory mechanisms. Biochemical and functional data described herein reveal that AMPK has ability to inhibit VSMC proliferation by inhibiting cell-cycle progression, possibly by increasing PP-2A within the nucleus. Additionally, we report that AMPK has ability to inhibit VSMC migration, presumably via inhibition of VASP anticapping actions on actin polymerization and increasing focal adhesion (FA) integrity. Additionally, AMPK shows ability to inhibit extracellular matrix degradation by MMP-9, which we suggest is under control of inhibitory TIMP-1. Taken together, these novel data suggest that AMPK employs both intraand extracellular inhibitory signals to effectively increase VSMC spatial stability while also inhibiting cell-cycle progression in an effort to promote cell senescence.
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